Enovis Corporation (ENOV) News
Follow Enovis Corporation (ENOV) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 31 public stories across 11 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Enovis Climbs on Swing to 3Q Profit, Higher Sales
By Connor HartShares of Enovis gained after the medical-technology company swung to a profit and logged higher sales in the recent quarter, prompting it to raise its full-year outlook.The stock rose 12%, to $27.44, midda
EARNINGS | Nov 05, 2026, 05:05 PM UTC
M
Enovis Shares Rise More Than 16% After Fiscal Q3 Beat
Enovis shares rose more than 16% on Thursday after the company reported a fiscal third-quarter beat.
EARNINGS | Nov 05, 2026, 03:10 PM UTC
M
Enovis Reports Q3 Sales of $559 Million, Raises 2026 Guidance
Enovis reported 5% organic sales growth and adjusted EPS of $0.88, above the FactSet consensus estimate of $0.77. It raised its full-year adjusted EPS outlook to $3.58-$3.79 and adjusted EBITDA outlook to $428-$438 milli
EARNINGS | Nov 05, 2026, 02:04 PM UTC
M
Enovis Sees FY Organic Revenue Growth of 5%
EARNINGS | Nov 05, 2026, 11:50 AM UTC
M
Enovis Q3 EPS Beats Estimates and Raises Full-Year Profit Outlook
EQUITY | Nov 05, 2026, 11:37 AM UTC
M
Enovis Reports Third-Quarter Revenue of $558.73 Million and EPS of $0.06
Enovis said third-quarter sales rose 1.8% year over year. Growth from existing businesses across both segments more than offset the Dr. Comfort divestiture and unfavorable currency translation; earnings improved from a y
EQUITY | Nov 05, 2026, 11:31 AM UTC
M
Enovis Reports Q3 Revenue of $558.7M
Enovis reported Q3 revenue of $558.7 million, compared with a FactSet estimate of $557.1 million.
EQUITY | Nov 05, 2026, 11:15 AM UTC
M
Enovis Swings to Q3 Net Income of $3.42 Million
EARNINGS | Nov 05, 2026, 11:12 AM UTC
M
Enovis Reports Third-Quarter 2026 Results
Third-quarter sales grew 2% on a reported basis and 5% organically.
EQUITY | Nov 05, 2026, 11:07 AM UTC
M
Enovis Q3 Gross Margin 60.8%
EARNINGS | Nov 05, 2026, 11:06 AM UTC
M
Enovis Q3 sales reach $558.725 million versus $557 million estimate
EARNINGS | Nov 05, 2026, 11:04 AM UTC
H
Transcript: Enovis Q2 2026 Earnings Conference Call
Enovis (NYSE: ENOV ) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. APIs provide real-time access to earnings call transcrip
LIVE | Oct 06, 2026, 12:35 PM UTC
L
Nyxoah Appoints Liam Kelly as Chief Executive Officer
REGULATED INFORMATIONINSIDE INFORMATIONNyxoah Appoints Liam Kelly as Chief Executive OfficerFurther strengthening the Company’s strategic U.S. presence and focusMont-Saint-Guibert, Belgium — September 28, 2026, 10:30 pm
NEWS | Sep 28, 2026, 08:32 PM UTC
L
ENOV - Enovis becomes first multi-registry industry sponsor of AAOS Registry Program
ENOV - Enovis becomes first multi-registry industry sponsor of AAOS Registry Program
NEWS | Sep 22, 2026, 04:02 PM UTC
M
ENOV Amplitude acquisition targets 50% FCF conversion next year
ENOV says the Amplitude acquisition strengthens its robotics capabilities and supports a planned 2028 U.S. knee launch. It targets 50% free cash flow conversion next year and 70-80% by 2029, supported by stable ortho con
MNA | Sep 08, 2026, 06:28 PM UTC
L
Wells Fargo cuts Enovis price target to $33 from $39
Wells Fargo lowered its Enovis price target to $33.00 per share from $39.00, according to Benzinga ratings actions reported by TradingView News.
EQUITY | Sep 02, 2026, 02:48 PM UTC
L
Enovis price target cut to $47 from $55 by Citizens
Citizens cut its Enovis price target to $47.00 per share from $55.00, per Benzinga ratings actions via TradingView News.
EQUITY | Sep 02, 2026, 01:00 PM UTC
L
Enovis maintained at Buy; Freedom Capital Markets cuts target
Freedom Capital Markets reiterated Enovis as Buy and cut its price target to $36.00 from $41.00, per Benzinga/TradingView News.
EQUITY | Sep 02, 2026, 12:14 PM UTC
M
BTIG cuts Enovis price target to $36 from $40
BTIG cut its Enovis price target to $36.00 per share from $40.00, per Benzinga ratings actions.
EQUITY | Sep 02, 2026, 09:49 AM UTC
M
ENOV to acquire eCential Robotics for €155M plus milestones
ENOV will acquire eCential Robotics to accelerate entry into surgical robotics, focused on knee and shoulder applications using a unified technology platform. Deal value is €155M plus milestones, expected to drive growth
MNA | Sep 01, 2026, 06:05 PM UTC
M
ENOV to pay €155M upfront for eCential Robotics, with up to €35M milestones
ENOV said it will acquire eCential Robotics to accelerate its orthopedic enabling technology strategy, with a €155M upfront payment and up to €35M in milestones.
MNA | Sep 01, 2026, 01:46 PM UTC
L
ENOV to acquire eCential Robotics in €155M deal
ENOV will acquire eCential Robotics in a €155M deal plus milestones, targeting a 2026 close and expecting commercial traction in 2028, alongside long-term margin and cash flow improvements.
EARNINGS | Sep 01, 2026, 01:27 PM UTC
M
Enovis to enter definitive purchase agreement; close in 4Q
Enovis and ECentral expect to enter into a definitive purchase agreement, with an expected close in 4Q.
EQUITY | Sep 01, 2026, 10:47 AM UTC
L
ENOV - eCential Robotics Announces Binding Offer from Enovis
ENOV - eCential Robotics Announces Binding Offer from Enovis
EQUITY | Sep 01, 2026, 10:46 AM UTC
M
eCential Robotics announces binding offer from Enovis
eCential Robotics said Enovis entered a binding offer under which eCential Robotics’ platform would join Enovis’ enabling technology portfolio.
EQUITY | Sep 01, 2026, 10:45 AM UTC
M
Enovis makes binding offer to acquire eCential Robotics
Enovis (ENOV) says it has made a binding offer to acquire eCential Robotics.
MNA | Sep 01, 2026, 10:39 AM UTC
L
ENOV - Enovis to Participate in the 2026 Wells Fargo Healthcare Conference
ENOV - Enovis to Participate in the 2026 Wells Fargo Healthcare Conference
EQUITY | Aug 31, 2026, 08:15 PM UTC
L
Enovis Affirms FY2026 Adj EPS Guidance of $3.52-$3.73 vs $3.65 Est; Affirms FY2026 Sales Guidance of $2.310B-$2.370B vs $2.345B Est
Enovis (NYSE: ENOV ) affirms FY2026 Adj EPS guidance from $3.52-$3.73 to $3.52-$3.73 vs $3.65 analyst estimate. Affirms FY2026 sales outlook from $2.310 billion-$2.370 billion to $2.310 billion-$2.370 billion vs $2.345 b
EARNINGS | Aug 06, 2026, 10:05 AM UTC
L
ENOV - Enovis Announces Second Quarter 2026 Results
ENOV - Enovis Announces Second Quarter 2026 Results
EARNINGS | Aug 06, 2026, 10:05 AM UTC
L
BAX DXCM ENOV HSIC NUE OVV OZK TFII ABT AMZN ATRC BBNX BKR BSX CEG MCB NRG RXST SGHT TNDM VST PT changes @ UBS
BAX DXCM ENOV HSIC NUE OVV OZK TFII ABT AMZN ATRC BBNX BKR BSX CEG MCB NRG RXST SGHT TNDM VST PT changes @ UBS
EQUITY | Jul 28, 2026, 11:47 AM UTC
L
4 Top Growth Stocks Worth Buying Under $100 Today
2026-07-03 08:50:00 ET Not every great investment story comes from a household name. Sometimes the best opportunities are found in overlooked industrial and
EQUITY | Jul 03, 2026, 12:54 PM UTC